Selective high affinity α3β4 nicotinic acetylcholine receptor antagonists
US10085975B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2017 |
| Grant date | Oct 2, 2018 |
| Priority date | — |
| Expiry date | Apr 23, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are novel and selective high affinity α3β4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the α3β4 nicotinic acetycholine receptor using the compounds and compositions disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.